A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Recruiting

Phase 3

BCG vs. TAR-210A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Sponsor:

Janssen Research & Development, LLC

Code:

NCT06919965

Conditions

Non-Muscle Invasive Bladder Neoplasms

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TAR-210

Mitomycin C

Gemcitabine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-19. This information was provided to ClinicalTrials.gov by Janssen Research & Development, LLC on 2025-10-10.